牛牛AI助手已提取核心信息
AbbVie Inc. officer Perry C Siatias is set to sell 9,911 common shares of the company on February 29, 2024, according to a recent filing. The shares, valued at an aggregate market value of $1,756,912.07, were acquired as performance shares directly from the issuer on February 28, 2024. This transaction follows a recent history of sales by Siatias over the past three months, totaling 16,672 shares for gross proceeds of $2,937,556.66. The planned sale is part of a trading plan adopted on November 1, 2023.
AbbVie Inc. officer Perry C Siatias is set to sell 9,911 common shares of the company on February 29, 2024, according to a recent filing. The shares, valued at an aggregate market value of $1,756,912.07, were acquired as performance shares directly from the issuer on February 28, 2024. This transaction follows a recent history of sales by Siatias over the past three months, totaling 16,672 shares for gross proceeds of $2,937,556.66. The planned sale is part of a trading plan adopted on November 1, 2023.
根据最近的一份文件，艾伯维公司高管佩里·西亚蒂亚斯定于2024年2月29日出售该公司的9,911股普通股。这些股票的总市值为1,756,912.07美元，于2024年2月28日作为绩效股票直接从发行人手中收购。该交易遵循了西亚蒂亚斯在过去三个月中的近期销售记录，共计16,672股股票，总收益为2,937,556.66美元。计划中的出售是2023年11月1日通过的交易计划的一部分。
根据最近的一份文件，艾伯维公司高管佩里·西亚蒂亚斯定于2024年2月29日出售该公司的9,911股普通股。这些股票的总市值为1,756,912.07美元，于2024年2月28日作为绩效股票直接从发行人手中收购。该交易遵循了西亚蒂亚斯在过去三个月中的近期销售记录，共计16,672股股票，总收益为2,937,556.66美元。计划中的出售是2023年11月1日通过的交易计划的一部分。
有用
没用
该公告为独立文件：